<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sublingual immunotherapy (SLIT) tablets: Labeling differences among United States products</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sublingual immunotherapy (SLIT) tablets: Labeling differences among United States products</h1>
<div class="graphic"><div class="figure"><div class="ttl">Sublingual immunotherapy (SLIT) tablets: Labeling differences among United States products</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Grastek</td> <td class="subtitle1">Oralair</td> <td class="subtitle1">Ragwitek</td> <td class="subtitle1">Odactra</td> </tr> <tr> <td><strong>Components</strong></td> <td> <p>Timothy grass pollen extract</p> Cross-reactive with: <ul class="decimal_heading"> <li>Timothy</li> <li>Orchard</li> <li>Kentucky Blue</li> <li>Perennial Rye</li> <li>Sweet Vernal</li> <li>Fescue</li> <li>Redtop</li> </ul> </td> <td>Pollen extracts of 5 grasses: <ul class="decimal_heading"> <li>Timothy</li> <li>Orchard</li> <li>Kentucky Blue</li> <li>Perennial Rye</li> <li>Sweet Vernal</li> </ul> </td> <td>Short ragweed pollen extract</td> <td>House dust mite allergen extract from <em>Dermatophagoides farinae</em> and <em>D. pteronyssinus</em></td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Indications</strong></td> <td>Grass pollen-induced allergic rhinitis with or without conjunctivitis</td> <td>Grass pollen-induced allergic rhinitis with or without conjunctivitis</td> <td>Short ragweed pollen-induced allergic rhinitis with or without conjunctivitis</td> <td>Dust mite-induced allergic rhinitis with or without conjunctivitis</td> </tr> <tr> <td><strong>Approved for ages</strong></td> <td>5 to 65 years</td> <td>10 to 65 years</td> <td>5 to 65 years</td> <td>12 to 65 years</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Required testing</strong></td> <td>Positive skin test <strong>or</strong> in vitro testing for IgE antibodies to Timothy grass <strong>or</strong> any of the cross-reactive grass species</td> <td>Positive skin test <strong>or</strong> in vitro testing for IgE antibodies to <strong>any</strong> of the 5 grass species in the tablet</td> <td>Positive skin test <strong>or</strong> in vitro testing for IgE antibodies to short ragweed</td> <td>Positive skin test with a house dust mite extract <strong>or</strong> in vitro testing for IgE antibodies to <em>Dermatophagoides farinae</em> or <em>D. pteronyssinus</em></td> </tr> <tr> <td><strong>Dose</strong></td> <td>2800 BAU single dose tablet, daily</td> <td> <p>300 IR in adults (ages: 18 to 65 years)</p> In children (ages: 10 to 17 years) step-up over three days, as tolerated: <ul class="decimal_heading"> <li>Day 1: 100 IR</li> <li>Day 2: 2× 100 IR</li> <li>Day 3: 300 IR</li> </ul> </td> <td>12 Amb a 1 unit single dose tablet, daily</td> <td>12 SQ-HDM unit single dose tablet, daily</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Method of administration</strong></td> <td>Place tablet under the tongue until it completely dissolves; do <strong>not</strong> swallow for at least one minute</td> <td>Place tablet under tongue for at least one minute or until completely dissolved, and then swallow</td> <td>Place tablet under the tongue until it completely dissolves; do <strong>not</strong> swallow for at least one minute</td> <td>Place tablet under the tongue until it completely dissolves; do <strong>not</strong> swallow for at least one minute</td> </tr> <tr> <td><strong>Initiation</strong></td> <td>12 weeks prior to grass season</td> <td>16 weeks prior to grass season</td> <td>12 weeks prior to ragweed season</td> <td>Can be started anytime</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Duration</strong></td> <td>Prior to and through relevant grass season; may be continued on a perennial basis over 3 years for sustained effectiveness</td> <td>Prior to and through relevant grass season</td> <td>Prior to and through relevant ragweed season</td> <td>Year-round</td> </tr> <tr> <td><strong>Data on safety of reinitiating treatment after a missed dose</strong></td> <td>In clinical trials, treatment interruptions for up to 7 days were allowed</td> <td>Data not available</td> <td>In clinical trials, treatment interruptions for up to 7 days were allowed</td> <td>In clinical trials, treatment interruptions for up to 7 days were allowed</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Contraindications</strong></td> <td> <ul> <li>Severe unstable or uncontrolled asthma</li> <li>History of any severe systemic allergic reaction</li> <li>History of any severe local reaction after taking SLIT</li> <li>Hypersensitivity to inactive ingredients in the product</li> <li>History of eosinophilic esophagitis</li> </ul> </td> <td> <ul> <li>Severe unstable or uncontrolled asthma</li> <li>History of any severe systemic allergic reaction</li> <li>History of any severe local reaction after taking SLIT</li> <li>Hypersensitivity to inactive ingredients in the product</li> <li>History of eosinophilic esophagitis</li> </ul> </td> <td> <ul> <li>Severe unstable or uncontrolled asthma</li> <li>History of any severe systemic allergic reaction</li> <li>History of any severe local reaction after taking SLIT</li> <li>Hypersensitivity to inactive ingredients in the product</li> <li>History of eosinophilic esophagitis</li> </ul> </td> <td> <ul> <li>Severe unstable or uncontrolled asthma</li> <li>History of any severe systemic allergic reaction</li> <li>History of any severe local reaction after taking SLIT</li> <li>Hypersensitivity to inactive ingredients in the product</li> <li>History of eosinophilic esophagitis</li> </ul> </td> </tr> <tr> <td><strong>Inactive ingredients</strong></td> <td>Gelatin (fish source), mannitol, sodium hydroxide</td> <td>Mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, lactose monohydrate</td> <td>Gelatin (fish source), mannitol, sodium hydroxide</td> <td>Gelatin (fish source), mannitol, sodium hydroxide</td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Asthma patients included in clinical trials</strong></td> <td>Not studied in patients with moderate or severe asthma or in patients who require daily medication to treat asthma</td> <td>Not studied in patients with moderate or severe asthma or in any subjects who require daily medication to treat asthma</td> <td>Trials allowed patients who required daily low doses of inhaled glucocorticoids to treat asthma</td> <td>Trials allowed patients with mild-to-moderate asthma that required, at most, a medium daily dose of an inhaled glucocorticoid to treat asthma</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table highlights differences in the product labeling among tablet products for SLIT. Several important safety issues, which are the same for all products, are not included. Please refer to the accompanying UpToDate topic on sublingual immunotherapy for allergic rhinitis for a discussion of additional safety issues, use in patients with asthma, recommendations for administration of initial dose, data on safety of initiating treatment during pollen season, and evaluation of patients with asthma exacerbations or recurrent asthma episodes while receiving SLIT.</div><div class="graphic_footnotes">IgE: immunoglobulin E; BAU: biologic allergy units; IR: index of reactivity; SQ-HDM: standardized units of potency for house dust mite allergen extract.</div><div id="graphicVersion">Graphic 95082 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
